Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 20/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679378 | 1.00 | EPHX2 (0.71) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2678163 | 0.92 | EPHX2 (0.80) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2678224 | 0.92 | EPHX2 (0.80) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2678165 | 0.92 | EPHX2 (0.80) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL5039338 | 0.91 | EPHX2 (0.58) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2678463 | 0.88 | EPHX2 (0.69) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2678460 | 0.88 | EPHX2 (0.69) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2677572 | 0.86 | EPHX2 (0.70) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2678188 | 0.86 | EPHX2 (0.70) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2678184 | 0.86 | EPHX2 (0.70) | EPHX2CYP2C9CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173805-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2012-05-08 | — | — | US | claimed |
| US-8212032-B2 | sEH inhibitors and their use | GLAXOSMITHKLINE LLC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8173805-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100249137-A1 | Novel sEH Inhibitors and Their Use | GlaxoSmithKline, LLC | 2010-09-30 | — | — | US | disclosed |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249137-A1 | Novel sEH Inhibitors and Their Use | NCEH1, CTH, EPHX1 | EPHX2 8/4885CYP2C9 377/4885CYP3A4 211/4885 |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | NCEH1, EPHX1, FAH | EPHX2 4/4885CYP2C9 140/4885CYP3A4 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.